ARTICLE | Clinical News
Glecaprevir/pibrentasvir: Ph III ENDURANCE-3 data
November 28, 2016 11:28 PM UTC
Top-line data from 157 treatment-naïve, non-cirrhotic patients with chronic HCV genotype 3 infection in the open-label, international Phase III ENDURANCE-3 trial showed that once-daily 300/120 mg oral...